Literature DB >> 23836165

Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness.

Rafael López-Rojas1, Michael J McConnell, Manuel Enrique Jiménez-Mejías, Juan Domínguez-Herrera, Felipe Fernández-Cuenca, Jerónimo Pachón.   

Abstract

The fitness and virulence costs associated with the clinical acquisition of colistin resistance by Acinetobacter baumannii were evaluated. The growth of strain CR17 (colistin resistant) was less than that of strain CS01 (colistin susceptible) when the strains were grown in competition (72-h competition index, 0.008). In a murine sepsis model, CS01 and CR17 reached spleen concentrations when coinfecting of 9.31 and 6.97 log10 CFU/g, respectively, with an in vivo competition index of 0.016. Moreover, CS01 was more virulent than CR17 with respect to mortality and time to death.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23836165      PMCID: PMC3754302          DOI: 10.1128/AAC.00543-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii.

Authors:  Jennifer H Moffatt; Marina Harper; Ben Adler; Roger L Nation; Jian Li; John D Boyce
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

2.  Acinetobacter baumannii resistant to colistin alters its antibiotic resistance profile: a case report from Spain.

Authors:  Rafael López-Rojas; Manuel Enrique Jiménez-Mejías; José Antonio Lepe; Jerónimo Pachón
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

3.  Acinetobacter baumannii resistant to colistin with impaired virulence: a case report from France.

Authors:  Jean-Marc Rolain; Antoine Roch; Matthias Castanier; Laurent Papazian; Didier Raoult
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

4.  The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A.

Authors:  Luis A Arroyo; Carmen M Herrera; Lucia Fernandez; Jessica V Hankins; M Stephen Trent; Robert E W Hancock
Journal:  Antimicrob Agents Chemother       Date:  2011-06-06       Impact factor: 5.191

5.  Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii.

Authors:  Rafael López-Rojas; Juan Domínguez-Herrera; Michael J McConnell; Fernando Docobo-Peréz; Younes Smani; María Fernández-Reyes; Luis Rivas; Jerónimo Pachón
Journal:  J Infect Dis       Date:  2011-01-07       Impact factor: 5.226

6.  Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production.

Authors:  Jennifer H Moffatt; Marina Harper; Paul Harrison; John D F Hale; Evgeny Vinogradov; Torsten Seemann; Rebekah Henry; Bethany Crane; Frank St Michael; Andrew D Cox; Ben Adler; Roger L Nation; Jian Li; John D Boyce
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

Review 7.  Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models.

Authors:  Michael J McConnell; Luis Actis; Jerónimo Pachón
Journal:  FEMS Microbiol Rev       Date:  2012-06-18       Impact factor: 16.408

8.  The virulence variability of different Acinetobacter baumannii strains in experimental pneumonia.

Authors:  Matthieu Eveillard; Christophe Soltner; Marie Kempf; Jean-Paul Saint-André; Carole Lemarié; Catherine Randrianarivelo; Harald Seifert; Michel Wolff; Marie-Laure Joly-Guillou
Journal:  J Infect       Date:  2009-09-11       Impact factor: 6.072

9.  The cost of resistance to colistin in Acinetobacter baumannii: a proteomic perspective.

Authors:  María Fernández-Reyes; Manuel Rodríguez-Falcón; Cristina Chiva; Jerónimo Pachón; David Andreu; Luis Rivas
Journal:  Proteomics       Date:  2009-03       Impact factor: 3.984

10.  Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.

Authors:  Mark D Adams; Gabrielle C Nickel; Saralee Bajaksouzian; Heather Lavender; A Rekha Murthy; Michael R Jacobs; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

View more
  38 in total

Review 1.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 2.  Interplay Between Antibiotic Resistance and Virulence During Disease Promoted by Multidrug-Resistant Bacteria.

Authors:  Edward Geisinger; Ralph R Isberg
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

3.  Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.

Authors:  Zubair A Qureshi; Lauren E Hittle; Jessica A O'Hara; Jesabel I Rivera; Alveena Syed; Ryan K Shields; Anthony W Pasculle; Robert K Ernst; Yohei Doi
Journal:  Clin Infect Dis       Date:  2015-01-28       Impact factor: 9.079

4.  In vivo evolution to colistin resistance by PmrB sensor kinase mutation in KPC-producing Klebsiella pneumoniae is associated with low-dosage colistin treatment.

Authors:  Antonio Cannatelli; Vincenzo Di Pilato; Tommaso Giani; Fabio Arena; Simone Ambretti; Paolo Gaibani; Marco Maria D'Andrea; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

5.  Treatment pattern, prognostic factors, and outcome in patients with infection due to pan-drug-resistant gram-negative bacteria.

Authors:  Diamantis P Kofteridis; Angeliki M Andrianaki; Sofia Maraki; Anna Mathioudaki; Marina Plataki; Christina Alexopoulou; Petros Ioannou; George Samonis; Antonis Valachis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-01-13       Impact factor: 3.267

6.  Genomic Insights into Colistin-Resistant Klebsiella pneumoniae from a Tunisian Teaching Hospital.

Authors:  Nadia Jaidane; Rémy A Bonnin; Wejdene Mansour; Delphine Girlich; Elodie Creton; Garance Cotellon; Cherifa Chaouch; Noureddine Boujaafar; Olfa Bouallegue; Thierry Naas
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

7.  Antibiotic Combinations That Enable One-Step, Targeted Mutagenesis of Chromosomal Genes.

Authors:  Wonsik Lee; Truc Do; Ge Zhang; Daniel Kahne; Timothy C Meredith; Suzanne Walker
Journal:  ACS Infect Dis       Date:  2018-03-23       Impact factor: 5.084

8.  Polymyxin resistance caused by mgrB inactivation is not associated with significant biological cost in Klebsiella pneumoniae.

Authors:  Antonio Cannatelli; Alfonso Santos-Lopez; Tommaso Giani; Bruno Gonzalez-Zorn; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

9.  Protective Effect of a Synbiotic against Multidrug-Resistant Acinetobacter baumannii in a Murine Infection Model.

Authors:  Takashi Asahara; Akira Takahashi; Norikatsu Yuki; Rumi Kaji; Takuya Takahashi; Koji Nomoto
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

10.  In Vitro Activity of the Novel Antimicrobial Peptide Dendrimer G3KL against Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa.

Authors:  João Pires; Thissa N Siriwardena; Michaela Stach; Regula Tinguely; Sara Kasraian; Francesco Luzzaro; Stephen L Leib; Tamis Darbre; Jean-Louis Reymond; Andrea Endimiani
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.